The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the ...

In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI ®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of ...

Legend Biotech (LEGN) has released an update. Legend Biotech’s CARVYKTI therapy, featured at the American Society of Hematology meeting, ...

Genscript Biotech (HK:1548) has released an update. Genscript Biotech’s associate, Legend Biotech, is making strides in the treatment of ...

Legend Biotech Corp (NASDAQ:LEGN), a biopharmaceutical company specializing in novel cell therapies for oncology, has been making waves in the healthcare sector with its flagship product, Carvykti. As ...

Legend Biotech has established itself as a key player in the multiple myeloma (MM) treatment space, primarily due to the success of Carvykti. This chimeric antigen receptor T-cell (CAR-T ...

SOMERSET, N.J. - Legend Biotech Corporation (NASDAQ: LEGN), a global biotechnology company specializing in cell therapy, announced Monday the appointment of Alan Bash as the President of CARVYKTI ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...